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Animals often  succumb  to  syngeneic spontaneous  or passaged tumors  even  though 
these  tumors  generally bear  tumor-specific antigens to  which  the  animals  should re- 
spond.  This  is  probably  due  to  the  fact  that  tumor-bearing  animals  are  frequently 
immunosuppressed.  A  variety  of mechanisms  appear  to  be  involved  in  this  tumor- 
associated anergy. Serum blocking factors consisting of antigens, antibodies, or antigen- 
antibody complexes which prevent functioning of tumor reactive lymphocytes are found 
in a  variety of viral and carcinogen-induced tumor systems (1-5).  Immunosuppressive 
substances  have  been  found in sera  and  ascitic fluid of mice bearing plasmacytomas, 
Ehrlich  ascites tumors,  and  mammary  adenocarcinomas  (6-8).  In  vitro  studies  have 
shown that cell-free extracts or soluble factors released from mastocytomas, methylchol- 
anthrene-induced tumors, fibrosarcomas, and several human tumors are immunosuppres- 
sive  (9-12).  Free  virus  has  been  implicated as  being directly  immunosuppressive  in 
infections with Friend virus and radiation-induced leukemia virus (13-15). Direct tumor 
cell contact  with  immunocompetent  lymphocytes appears to  be  required for  immuno- 
suppression  in  one  methylcholanthrene-induced  tumor  system  (16).  Cells  capable  of 
inhibiting  in  vitro  phytohemagglutinin  (PHA) 1 lymphocyte stimulation  are  found  in 
spleens of Moloney sarcoma tumor-bearing mice (17, 18). Autoimmunity in some tumor- 
bearing mice may be responsible for deletion of specific tumor-reactive lymphocytes (19). 
Immune failure resulting from the onset of leukemia in AKR mice and the relationship 
of this immune failure to the leukemia transforming event has been discussed for many 
years (20-22).  A  generalized failure of the AKR immune  surveillance mechanism does 
not appear to be the cause, but rather the consequence, of the onset of overt leukemia in 
these mice (Panfili and Golub, to be published; 23).  Other workers have shown altered 
mitogeneic responsiveness of leukemic AKR cells to concanavalin A  (Con A) (24)  and 
PHA (24,  25),  altered migration patterns and expression of theta  antigen on leukemic 
thymocytes (25),  and altered uptake and distribution of antigen in the leukemic spleen 
(26),  but the relevance of these altered conditions to the cause of failure of the immune 
system of leukemic AKR mice is not clear. 
We report here in vitro studies on the responsiveness of leukemic AKR cells to 
antigen  and  the  effects  of these  leukemic  cells  on  the  immune  responses  of 
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normal syngeneic and allogeneic lymphocyte populations. Leukemic AKR cells 
are capable of suppressing in vitro antibody responses of normal AKR lympho- 
cytes as well as AKR cell-mediated responses to DBA mastocytomas (Panfili and 
Golub, to be published). We have chosen in vitro antibody production as a model 
system for investigating the suppressive mechanism of leukemic AKR cells. Our 
in  vitro  analysis  of  suppression  by  leukemic  AKR  cells  suggests  that  the 
mechanism  of  immunosuppression  in  leukemic  AKR  mice  is  by  direct  cell 
contact, requires the tumor and normal cells to be syngeneic or semiallogeneic, 
and is overcome by an allogeneic effect. 
Materials and Methods 
Mice.  AKR/J mice, 5-8 wk old, as well as retired breeders, were obtained from The Jackson 
Laboratories, Bar Harbor, Maine. CBA, C57BL/6,  C57BL/10  (B10),  B10.A, B10.BR,  129, C3H/Fe, 
AKR.M, C58, DBA/2, [C57BL/6  x  DBA/2]F, (BDF,), [AKR x  C57BL/10]F, (AKB10), and [AKR x 
DBA/2 F,] (AKD2F,) were bred in our animal facilities using stocks obtained from The Jackson 
Laboratories.  AKR.H-2  b mice  were  the  generous gift  of Dr.  Edward  Boyse,  Sloan-Kettering 
Institute, and the C57BL/6.AKR were the generous gift of Dr. Frank Lilly, Albert Einstein College 
of Medicine. Mice were housed five to a  cage and maintained on high chlorine, low pH water. 
AKR/J mice less than 4-mo old were used as a  source of normal AKR cells, although older 
nonleukemic AKR mice gave  normal responses. Overtly leukemic mice were characterized by 
their massively enlarged thymuses, spleens, lymph nodes, and livers. 
In  Vitro  Cultures.  In vitro immune responses were performed by the method of Mishell and 
Dutton (27). Lymphoid cells were cultured in 35-mm Falcon petri dishes (Falcon Plastics, Oxnard, 
Calif.) or, for cell contact experiments, in Karush type modified equilibrium dialysis chambers 
(Bellco Glass Inc., Vineland, N. J.) separated by 0.2  ~m Nuclepore filters (General Electric Co., 
Plesanton, Calif.) (28). 
Antigens and Assays.  Sheep red blood cells (SRBC) were obtained from Colorado Serum Co., 
Denver, Colo. and were used as immunogen at 107 cells per culture. Trinitrophenyl lipopolysaccha- 
ride (TNP-LPS) was prepared from trinitrobenzene sulfonic acid and lipopolysaccharide (LPS) by 
the method of Jacobs and Morrison (29); 0.1 ~g of TNP-LPS were added per culture. Plaque assays 
were performed by the Cunningham modification of the Jerne plaque  assay (30). Target cells 
consisted of SRBC  or lightly-conjugated trinitrophenyl horse red blood cells (TNP-HRBC)  pre- 
pared by the method of Rittenberg and Pratt (31). 
Irradiation  of Cells.  Leukemic  or  normal  cells  were  suspended to  107  cells/ml  in  Hank's 
balanced salt solution (Grand Island Biological Co.,  Berkeley, Calif.) plus 5% fetal calf serum 
(Grand Island Biological Co.) and X-irradiated at doses indicated in the text. The source was a GE 
Maxitron 300 machine (General Electric, Milwaukee, Wis.) operated at 250 kV and 15 mA with 0.25 
cm Cu and 1-mm A1 filtration at a head height of 51 cm (34 cm for 8,000 R). A dose of 50 R/min (160 
R/rain  for  8,000  R)  was  delivered over  a  uniform  area,  as  determined dosimetrically with  a 
Victoreen dosimeter (Victoreen Instrument Div.,  VLN Corp., Cleveland, Ohio). Irradiated cells 
were washed in Hank's and counted before use. 
Freezing Leukemic Cells.  Spleens, livers, and lymph nodes from overtly leukemic mice were 
dispersed in Hank's balanced salt solution (Grand Island Biological Co.) plus 5% fetal calf serum 
(Grand  Island Biological Co.).  Cells were suspended to 2  ×  107  per  ml  in  Dulbecco's Modified 
Eagle's Medium (Grand Island Biological Co.) plus 5~ fetal calf serum and 8~ dimethyl sulfoxide 
(Baker-reagent grade), and sealed in vials in  1-ml aliquots.  The vials were frozen in a  -70°C 
freezer and then placed in liquid N~.  Cells were thawed in a  37°C water bath and washed three 
times in buffer before use. 
Results 
Immune  Unresponsiveness  and  Suppressive  Effect  of  Leukemic  AKR 
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thymus-dependent antigen SRBC and show a  greatly reduced response to the 
thymus-independent antigen TNP-LPS in the in vitro Mishell-Dutton culture 
system (Table I). When normal AKR spleen cells are mixed with equal numbers 
of leukemic spleen or thymus cells, their ability to respond to SRBC is nearly 
abolished, and their ability to respond to TNP-LPS is reduced (Table I).  Cells 
from the enlarged lymph nodes and livers of leukemic mice are also capable of 
suppressing the  plaque-forming cells  (PFC)  responses  of normal  spleen  cells 
(Table I). 
To  establish  the  relationship  between  the  degree  of suppression  and  the 
proportion of leukemic cells added per  culture,  varying numbers of leukemic 
cells were added to a constant number (107) of normal cells (Fig. 1). The degree of 
suppression observed varied with cells from different individual leukemic mice; 
50% leukemic cells were usually required to reduce normal SRBC responses to 
less than 20% of control values, while 10% leukemic cells reduced responses to 
from 20 to 80% of control value. The variation in suppressive ability of cells from 
different mice may be a function of the proportion of leukemic cells present in 
the  organ being used  as  a  source  of leukemic cells,  and  thus the  degree  of 
metastatis of the leukemia, or may reflect inherent differences in suppressive 
ability of different leukemic cells. Leukemic cells which have been stored frozen 
in  liquid  nitrogen maintain full  suppressive  ability,  thus  allowing repeated 
examination of cells from individual mice (Table I).  The thymus-independent 
response  of normal  spleen  cells  to  TNP-LPS  was  always  more  resistant  to 
suppression by leukemic cells than the thymus-dependent response  to SRBC 
(Fig. 1); however, this is probably because LPS is capable of  overcoming immuno- 
TABLE  I 
Suppression  of Responses of Normal AKR Spleen Cultures by Leukemic AKR Thymus, 
Spleen, Lymph Node, and Liver Cells* 
Exp  Cells  SRBC  %  con-  TNP-LPS  %  con- 
no.  PFC/culture  trol  PFC/culture  trois 
i  Normal spleen  278 ± 74  205 ± 43 
Leukemic spleen  0  40 ± 25 
Normal spleen plus leukemic spleen  0  0  50 ±  8  24 
Normal spleen  1,260 ± 291 
Leukemic thymus  0 
Normal spleen  plus  leukemic  thymus  33 ± 21  3 
Normal spleen  2,731 -+ 450 
Leukemic spleen  0 
Normal spleen plus leukemic spleen  58 ± 48  2 
Normal spleen  plus  leukemic  thymus  313 x 53  11 
Normal  spleen  plus leukemic lymph  275 *-50  10 
node 
Normal spleen  574 ± 9 
Leukemic spleen  0 
Normal spleen  plus leukemic spleen  125 ± 18  22 
Normal spleen plus leukemic thymus  93  ±  27  16 
Normal spleen plus leukemic liver  55 ±  8  10 
1,253 -+ 81 
35±3 
615 -+  175 
NT§ 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
NT 
49 
* 107  normal AKR  spleen cells  or I0  ~  normal AKR spleen  cells  plus 107  leukemic cells  were added per  culture. 
SRBC were  added  at  107  cells  per  culture  and  TNP-LPS at  I  ~g  per  culture.  TNP-LPS cultures  were  assayed  at 
day 3 and  SRBC cultures  at  day 4. 
Percent control,  PFC/culture  of  leukemic  plus normal cells  divided  by PFC/culture  of  normal cells. 
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FIG.  1.  Titration  of suppressive activity  of leukemia  cells after  freezing or  irradiation. 
Varying numbers of leukemic cells (107,  5  ×  106, 2.5  x  106, or 1.25  ×  106) were added to 107 
normal AKR spleen cells plus SRBC or TNP-LPS (resulting in 50, 33, 20, and 12% leukemic 
cells per culture). Cultures containing 107 normal cells alone or 107 leukemic cells alone plus 
antigen served as controls. TNP-LPS cultures were assayed on day 3 and SRBC cultures on 
day 4.  Values are expressed as percent of control PFC (i.e.,  PFC of 107 normal spleen cells) 
per culture.  Leukemic spleen and thymus cells in parts A  and B  were  obtained  from the 
same leukemic mouse and were used unfrozen (O  =  TNP-LPS; •  =  SRBC).  Leukemic cells 
in part C were obtained from a  different leukemic mouse and were used after freezing (O  = 
leukemic thymus; •  =  leukemic spleen). Leukemic thymus cells in part D were from a third 
leukemic mouse and were used unfrozen (O  =  8,000 R, TNP-LPS; •  =  unirradiated,  TNP- 
LPS;  A  =  8,000 R, SRBC;  •  =  unirradiated,  SRBC). 
suppression by leukemic cells (Roman and Golub, manuscript in preparation). 
Leukemic cells obtained  from  mice bearing spontaneous  leukemias  did not 
replicate  well  in  vitro,  and  thus  the  suppressive effect exerted by these  cells 
could not be attributed  to their  simply  having  "overgrown"  the  cultures.  As 
proof of this,  leukemic  cells  which  have  been X-irradiated  with  8,000  R  still 
possess full suppressive ability (Fig.  1 D). 
Kinetics  of Suppression.  To  determine  if development  of the  in  vitro  im- 
mune  response  was  sensitive  to  inhibition  by leukemic  cells throughout  the 
culture period,  107 leukemic cells were added to cultures containing 107 normal 
spleen  cells  plus  SRBC  at  various  days  of culture.  For  consistency,  frozen 
leukemic cells from the same mouse were used throughout the experiment.  107 486  LEUKEMIA  IN  AKR  MICE 
normal spleen cells without  added leukemic cells served as controls.  Leukemic 
cells were added on days 0,  1,  2, 3,  or 4,  and cultures were assayed on day five, 
which  was the  day of peak control response.  The results  (Fig.  2)  expressed as 
percent  of control  value  show  that  leukemic  cells were  able  to  arrest  further 
development of PFC  even when added at the 4th day of culture. 
Requirement  for Cell Contact.  To establish  whether  soluble factors play a 
role  in  leukemic  cell  suppression  of normal  PFC  response,  leukemic  cells  or 
mixtures  of leukemic  and  normal  cells  were  cultured  for  4  days  in  Mishell- 
Dutton  culture  conditions.  Medium  from these  cultures  was  centrifuged  and 
filtered through 0.45/~m filters or left unfiltered. 0.5 ml of the supernatant fluid 
was mixed with an equal volume of fresh medium and used to culture  normal 
AKR  spleen  cells.  The  PFC  responses  of  these  cultures  were  not  reduced, 
although  the leukemic cells themselves,  which had been in culture for 4 days, 
retained their immunosuppressive capabilities (Table II). 
To further establish the failure of leukemic cells to elaborate soluble suppres- 
sive factors,  leukemic and  normal cells were cultured  opposite one another in 
Karush  type chambers separated  by 0.2  /~m Nuclepore filters as described by 
Calkins and Golub (28).  In such chambers medium is free to flow from one cell 
population to another,  but cell contact is prohibited. The data in Table III show 
that  normal  cells  grown  transfilter  from  leukemic  cells  are  able  to  generate 
normal  anti-SRBC  responses.  This  suggests  that  cell  contact  is  needed  for 
suppression. 
Specificity of Suppression  for Syngeneic Cells.  A  requirement for cell con- 
tact between leukemic and normal cells could indicate that a specific recognition 
of cell surface moieties is necessary for suppression to occur. We therefore tested 
the  ability  of leukemic  AKR  cells  to  suppress  a  variety  of allogeneic  cells. 
Leukemic cells from 80%  (24 of 30) of the  leukemic AKR mice which we have 
tested for specificity have not been suppressive for allogeneic cells, as shown by 
the  following experiments.  Leukemic  AKR cells  are  unable  to  suppress  anti- 
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Fro.  2.  Cultures of 107 normal spleen cells were challenged with SRBC on day 0. On days 0 
through 4, 107 leukemic spleen cells were added to the cultures and cultures were assayed on 
day 5.  Frozen  leukemic cells from one leukemic  mouse were used throughout.  Cultures 
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TABLE II 
Test for Suppression  of Normal AKR Spleen Cell PFC Responses  by Supernates  of 
Leukemic or Leukemic plus Normal Cultures 
Cells*  Supernate sources  Filtered  PFC/culture 
Normal AKR  --  -  440  ±  53 
Normal AKR  Leukemic spleen  -  458  ±  31 
Normal AKR  Leukemic spleen  +  482  ~  21 
Normak AKR  Leukemic plus normal  -  463  ±  82 
Normal AKR  Leukemic plus normal  +  453  ±  21 
* 107 normal AKR spleen cells plus SRBC were added to all cultures; PFC assays were performed 
on day 4. 
S Cultures of leukemic spleen cells alone or mixtures of leukemic spleen cells plus normal AKR 
spleen  cells  were  harvested  at  day  4  of culture,  pelleted at  1,800  RPM  for 30  min,  and  the 
supernates filtered through 0.45 pm filters or left unfiltered. Filtered or unfiltered supernates 
(0.5 ml) were added to 107 normal AKR spleen cells plus SRBC.  Control experiments indicated 
that the leukemic cells used for the generation of these supernates were capable of suppressing 
SRBC responses to 6% of control when used fresh and to 7% of control when used after 4 days in 
culture. 
TABLE III 
Lack of Suppression  of Normal AKR SRBC Response by Leukemic AKR Cells Across a 
Filter 
Group  Chamber side 1"  Chamber side 2 
I  Normal AKR  +  SRBC  Normal AKR  +  SRBC 
757  -+ 1065  690  ±  36 
II  Normal AKR  +  SRBC  Normal AKR  -  SRBC 
682  -+ 232  160 ±  57 
III  Normal AKR  +  SRBC  Leukemic AKR +  SRBC 
1,155  ±  337  2  _+ 2 
IV  Normal AKR  +  SRBC 
795  ±  150 
Normal AKR +  leukemic AKR +  SRBC 
170 ±  26 
* Chambers were separated by 0.2 pm Nuclepore filters. Each side of the chamber contained 107 
normal AKR spleen cells with or without SRBC or 107 leukemic spleen cells plus SRBC, or 107 
normal plus 107 leukemic cells plus SRBC. 
S Mean PFC per chamber  ±  the SE of the mean for four replicate chambers.  PFC assays were 
performed on day 5. 
SRBC  responses  of allogeneic  cells  which  differ from  AKR  in both  background 
and H-2 genes,  such  as DBA/2,  C57BL/6,  BDF~,  129,  and  B10 (Table  IV).  DBA/2 
has  the  same  M  locus as AKR  (M-l, 32),  and  the  129 expresses  the  G~x Gross  vi- 
rus  antigen,  as does AKR  (33).  Leukemic  AKR  cells are  also unable  to suppress 
allogeneic  cells which  differ from  AKR  in background,  but  have  the same  or part 
of  the  same  H-2  haplotype  as  AKR  (H-2k),  such  as  C58,  CBA,  C3H, 
C57BL/6.AKR,  A, B10.A,  and  B10.BR  (Table  V). It is of interest  that  C58,  which 
like  AKR  has  a  high  incidence  of  leukemia,  is  not  suppressed  by  leukemic TABLE  IV 
Failure of Leukemic AKR Cells to Suppress Allogeneic Cells with both Background 
and H-2 Differences* 
Leukemic 
Exp  Strain  H-2 haplotype  AKR cells  PFC/culture  % control 
no.  added 
1  AKR  kkkkkk  --  557  ±  57 
Thymus  150  ±  45  27 
C57BL/6  bbbbbb  --  2,137  ±  345 
Thymus  2,143  ±  700  100 
2  AKR  kkkkkk  --  555  ±  120 
Thymus  43  -+  8  8 
B10  bbbbbb  --  1,530  ±  269 
Thymus  6,615  z  931  >100 
--  730  ±  204 
AKR  kkkkkk  Spleen  15  ±  5  2 
Thymus  22  ±  13  3 
dddddd  --  725  ±  265 
BDF~  Spleen  1,598  ±  153  >100 
bbbbbb  Thymus  878  ±  96  >100 
--  273  ±  16 
AKR  kkkkkk  Spleen  85  ±  18  31 
Thymus  50  ±  11  18 
--  1,034  ±  355 
DBA/2  dddddd  Spleen  2,190  ±  651  >100 
Thymus  1,072  ±  424  100 
--  5,557  ±  717 
C57BL/6  bbbbbb  Spleen  6,794  ±  358  >100 
Thymus  4,432  ±  287  80 
bbbbbb  --  2,902  ±  252 
BDF~  Spleen  6,524  ±  980  >100 
dddddd  Thymus  3,712  ±  334  >100 
--  1,072  ±  174 
B10  bbbbbb  Spleen  4,365  ±  370  >100 
Thymus  2,264  ±  513  >100 
--  929  ±  105 
129  bbbbbb  Spleen  1,469  ±  549  >100 
Thymus  1,267  ±  223  >100 
* 107  normal spleen cells  of  the strain indicated were cultured alone or with 107 leukemic spleen or 
thymus cells  plus SRBC. Fresh leukemic cells  from different leukemic mice were used for each 
experiment shown except experiment 1 in which frozen leukemic cells  were used. Cultures were 
assayed on day 4. Percent control refers  to PFC of  cultures with leukemic cells  divided by PFC of 
cultures without leukemic cells × 100.107 leukemic spleen cells  challenged with SRBC  gave zero 
PFC/culture in all experiments. 
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AKR cells.  Furthermore,  leukemic AKR cells  do  not  suppress  AKR.H-2  b or 
AKR.M cells with the same background as AKR but differing in H-2 haplotype 
(Table  VI).  AKR.M cells differ from AKR cells only at the D  region of H-2 
and the T/a locus (34). 
Thus,  it  appears  that  neither  background  nor H-2  similarities  alone  are 
sufficient for a cell to be suppressed by leukemic AKR cells, and that any genetic 
difference which can result in an  allogeneic reaction by normal cells toward 
foreign determinants on leukemic cells is sufficient to prevent suppression from 
occurring. We therefore investigated suppression in a semiallogeneic system in 
which the normal cells are unable to respond allogeneicaUy to leukemic cells. 
Under these conditions we found that the leukemic cells were able to suppress. 
This is shown in Table VII; the Fls of AKR and two nonsuppressible strains (B10 
and DBA/2)  are suppressed by leukemic AKR cells. 
Effect of Allogeneic Cells on Syngeneic Suppression.  To determine whether 
an allogeneic reaction was sufficient to overcome suppression, small numbers of 
irradiated allogeneic cells were added to cultures of normal AKR spleen cells 
plus leukemic AKR cells.  In this situation, the normal AKR cells are able to 
respond to determinants on the irradiated allogeneic cells. As shown in Table 
VIII, this allogeneic stimulation abrogates the suppressive ability of leukemic 
cells.  In fact,  addition of semiallogeneic cells overcomes suppression of AKR 
cells despite the fact that semiallogeneic cells are  themselves suppressed  by 
leukemic cells. The stimulation of PFC over background (i.e., AKR cells alone) 
caused by addition of irradiated semiallogeneic cells is, however, lower in the 
presence of leukemic cells (Table VIII). 
Discussion 
The debate as to whether a state of immunological anergy is the cause or the 
effect of neoplasia has been a continuing one for many years (35, 36). Our data 
suggest  that  in  the  case  of AKR  leukemias,  at  least,  the  neoplastic  cells 
themselves can induce a  state of anergy in normally functioning lymphocytes. 
This  leukemia-mediated suppression  of cells  which might otherwise respond 
against the tumor cells could have great significance in terms of the pathogen- 
esis of the leukemia in AKR mice.  We have investigated the suppression of a 
thymus-dependent antibody response here, but we have established that cell- 
mediated responses are suppressed by leukemic cells as well (Panfili and Golub, 
manuscript in preparation).  The fact that such functionally diverse organs as 
thymus, spleen, lymph node, and liver contain immunosuppressive cells (Table 
I) argues that the widely metastasized leukemic cells are themselves suppress- 
ing. However, it cannot yet be ruled out that transformed cells turn on suppres- 
sive function in normal cell populations, and that these cells have (or assume) a 
heterogeneous organ distribution. The nature of the suppressive cell or cells in 
leukemic AKR mice is currently under investigation. 
The thymus-independent TNP-LPS response of normal AKR spleen cells is 
more  resistant  to  suppression  by  leukemic cells than  the  thymus-dependent 
SRBC response  (Table  I  and Fig.  1).  This probably does not reflect inherent 
differences in sensitivity to suppression of either T or B cells, but more likely 
reflects the ability of LPS to overcome suppression (Roman and Golub, to be 490  LEUKEMIA  IN  AKR  MICE 
TABLE  V 
Failure of Leukemic AKR Cells to Suppress Allogeneic Cells with Background 
Differences and H-2 Similarities* 
Exp 
no. 
Leukemic 
Strain  H~  haplotype  AKR cells  PFC/culture  ~  control 
added 
--  878  +_  168 
AKR  kkkkkk  Spleen  25  _~  22  3 
Thymus  63  +_  58  7 
--  724  -+  179 
C58  kkkkkk  Spleen  907  _+  298  >100 
Thymus  1,230  +_  240  >100 
AKR  kkkkkk  --  2,731  _+  450 
Spleen  58  +_  48  0 
CBA  kkkkkk  --  392  x  128 
Spleen  410  _+  51  >100 
AKR  kkkkkk  --  555  ~  120 
Thymus  43  ±  8  8 
CBA  kkkkkk  --  120  _+  4 
Thymus  152  +  29  100 
C~H/Fe  kkkkkk  --  167  +_  11 
Thymus  207  -+  21  >100 
B10.A  kkkddd  --  2,745  +_  589 
Thymus  2,790  +_  153  100 
--  362  _+  65 
AKR  kkkkkk  Spleen  105  ±  19  29 
Thymus  12  _+  16  3 
--  848  ±  103 
CBA  kkkkkk  Spleen  817  ±  60  96 
Thymus  776  -+  79  92 
--  160  ±  22 
C3HfFe  kkkkkk  Spleen  315  +_  62  >100 
Thymus  401  +_  5  >100 
--  35_+8 
A  kkkddd  Spleen  337  ±  56  >100 
Thymus  218  +_  21  >100 
--  510  -+  224 
B10.A  kkkddd  Spleen  3,802  ±  587  >100 
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TABLE  V-Continued 
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Leukemic 
Exp  Strain  H-2 haplotype  AKR cells  PFC/culture  % control 
no.  added 
--  967  ±  88 
B10.BR  kkkkkk  Spleen  7,065  ±  670  >100 
Thymus  4,287  ±  143  >100 
--  539  ±  88 
C57BL/6.AKR  kkkkkk  Spleen  4,049  ±  550  >100 
Thymus  2,328  _-x 620  >100 
* 10  ~ normal spleen cells of the strain indicated were cultured alone or with 107 leukemic spleen or 
thymus cells plus SRBC. Fresh leukemic cells from different leukemic mice were used for each 
experiment shown. Cultures were assayed on day 4.  Percent control refers to PFC of cultures 
with leukemic cells  x  100.  The C57BL/6.AKR mice were  a  generous gift of Dr.  F.  Lilly,  107 
leukemic spleen cells challenged with SRBC gave zero PFC/culture in all experiments. 
TABLE  VI 
Failure of Leukemic AKR  Cells to Suppress Allogeneic Cells with AKR Background 
Similarities and H-2 Differences* 
Leukemic 
Exp  Strain  H-2 haplotype  AKR cells  PFC/culture  % control 
no.  added 
--  611  ±  108 
AKR  kkkkkk  Spleen  98  -  29  16 
Thymus  117  ±  45  19 
--  200  ±  35 
AKR.M  kkkkkq  Spleen  370  ±  97  >100 
Thymus  252  ±  37  >100 
645  ±  121 
AKR.H-2 b  bbbbbb  Spleen  990  ±  252  >100 
Thymus  877  ±  96  >100 
--  255  ±  30 
AKR  kkkkkk  Spleen  27  -  3  11 
Thymus  41  ±  37  16 
--  362  ±  51 
AKR.H-2 b  bbbbbb  Spleen  720  +- 42  >100 
Thymus  573  ±  79  >100 
* 107 normal spleen cells of the strain indicated were cultured alone or with 107 leukemic spleen or 
thymus cells plus SRBC.  Fresh leukemic cells from two different leukemic mice were used for 
the two experiments shown. Cultures were assayed on day 4,  Percent control refers to PFC of 
cultures with  leukemic cells divided by  PFC  of cultures without leukemic cells  ×  100.  The 
AKR,H-2  ~ mice were  a  generous gift from Dr.  Edward  Boyse.  107  leukemic spleen cells chal- 
lenged with SRBC gave zero PFC/culture in all experiments. 492  LEUKEMIA  IN  AKR  MICE 
TABLE  VII 
Ability of Leukemic AKR Cells to Suppress Semiallogeneic Cells* 
Leukemic AKR 
Strain  H-2 haplotype  cells added  PFC/culture  c/( control 
--  1,245  _+  246 
AKR  kkkkkk  Spleen  10  ±  8  0 
Thymus  40  ±  40  3 
--  5,115  ±  538 
B10  bbbbbb  Spleen  7,650  ±  420  >100 
Thymus  5,425  _+  962  >100 
--  802  ±  105 
DBA/2  dddddd  Spleen  905  ±  81  100 
Thymus  803  ±  18  100 
kkkkkk  --  458  ±  64 
AKD~F~  Spleen  30  -+  5  6 
dddddd  Thymus  40  -+  21  9 
kkkkkk  --  5,580  ±  562 
AKB10F~  Spleen  472  ±  69  8 
bbbbbb  Thymus  593  ±  9  11 
* 107 normal spleen cells of the strain indicated  were cultured alone or with  107 fresh leukemic 
spleen cells plus SRBC. Cultures were assayed on day 5. Percent control refers to PFC of cultures 
with leukemic cells divided by PFC of cultures without leukemic cells ×  100.  107 leukemic spleen 
cells challenged with SRBC gave zero PFC/culture in all experiments. 
published). The cell type(s) which are sensitive to suppression by leukemic AKR 
cells is presently being investigated.  However, the kinetic experiments (Fig. 2) 
would indicate that,  at least in this situation,  addition of leukemic cells after 
initiation of clonal expansion of B cells halts further B-cell proliferation.  Addi- 
tion of leukemic cells at later times during the culture period did not completely 
abolish  PFC,  suggesting  that  leukemic  cells  are  not  suppressing  by  killing 
spleen cells. 
The fact that leukemic AKR cells act as efficient immunosuppressants  when 
added at any time during the 4-day culture period suggests a  different mecha- 
nism of suppression than has been reported for other in vitro tumor suppressor 
systems  in  which  tumor  cells  must  be  added  within  24  h  after  initiation  of 
culture in order to suppress (9,  15). Irradiated  leukemic cells are fully suppres- 
sive (Table I), which also suggests a different mechanism of suppression than is 
found with Friend  virus-infected  cells  where  X-ray and  mitomycin C  abolish 
suppressive ability (15). 
Leukemic AKR cells require  contact  with  normal  lymphocytes to suppress 
their immune responses (Tables II and III). The fact that suppressive factors are 
not elaborated by leukemic cells explains why relatively large numbers of cells 
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TABLE  VIII 
An Allogeneic  Effect  Overcomes Suppression by Leukemic AKR Cells* 
Irradiated  cells  Leukemic AKR cells  Normal cells  PFC/culture  % control§  added~  added 
AKR  --  --  630  +-  114 
AKR  --  Spleen II  128  -+  46  20 
AKR  AKR$  --  728  ±  143 
AKR  AKR  Spleen  68  ±  23  I0 
AKR  DBA/2  --  3,305  ±  391 
AKR  DBA/2  Spleen  5,332  ±  286  >100 
AKR  AKD~F,  --  3,105  ±  109 
AKR  AKD2F,  Spleen  1,845  ±  338  >100 
DBA/2  --  --  2,250  ±  478 
DBA/2  --  Spleen  2,588  ±  192  100 
AKRD2F,  --  --  1,343  ±  385 
AKRD2F,  --  Spleen  385  ±  140  28 
*  Normal  spleen  cells  of  the  strain  indicated  were  cultured  at  107  cells  per  culture.  106  X-irradiated 
cells  (2,000  R)  and/or  107  frozen  leukemic  spleen  cells  were added  where indicated.  SRBC were 
added  to  all  cultures  and  cultures  were assayed  on  day  4. 
* 107  irradiated  AKR, DBA/2, and  AKDzF, cells  challenged  with  SRBC gave  zero  PFC on  day  4  of 
cultures. 
§  Percent  control  refers  to  percent  of  PFC response  in  the  absence  of  irradiated  cells  or  leukemic 
cells. 
II  10T  leukemic  spleen  cells  challenged  with  SRBC gave  zero  PFC/culture  in  all  experiments. 
systems which are mediated by soluble factors,  a significant degree of  suppres- 
sion may be achieved with relatively few tumor cells  (9, 11, 15). 
This requirement for cell  contact led us to explore the degree of surface 
antigenic homology required for  suppression. Our data indicates that  homology 
either within the H-2 region or in background genes alone is not sufficient  to 
permit suppression by leukemic AKR  cells,  since a difference in either  H-2 or 
background genes prevents suppression (Tables IV, V, and VI).  The F,s  of  AKR 
and two nonsuppressible strains (B10 and DBA/2) were, however, suppressed 
(Table VII).  It  is  possible that  two genetic loci  are required for  suppression, one 
within the H-2 region and one outside. On the other hand, it may be that cell 
surface homology is  not required for suppression at all,  but rather that any cell 
capable of  making an allogeneic  response to  the  leukemic cell  determinants or  to 
any other foreign cell  surface antigens is able to escape suppression. The fact 
that normal AKR  cells  are not suppressed by leukemic AKR  cells  when irradi- 
ated allogeneic cells  are present argues that this may be the case (Table VIII). 
Bortin et al. reported a significant delay in onset of passaged AKR  leukemia 
after  injections  of  allogeneic  cells,  although these authors attributed  this  finding 
to a killing of  leukemic cells  by the allogeneic cells  (37). 
If the immunosuppressive  activity of the leukemic cell  is important in the 
pathogenesis of  the AKR  thymic leukemia and the suppression can  be overcome 
by allogeneic interaction, it  may be possible to alter  the course of  the disease  by 
treatment with allogeneic cells.  Experiments along this line are now in prog- 
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Summary 
Cells from the spleen,  thymus,  lymph node, and liver of leukemic AKR mice 
suppress  in  vitro  antibody  responses  of normal  syngeneic  and  semiallogeneic 
cells.  This suppression  can be mediated by irradiated  leukemic cells,  requires 
cell  contact  between  leukemic  and  normal  cells,  and  may occur  at  any  time 
during the in vitro culture period. Leukemic AKR cells do not suppress antibody 
responses of allogeneic cells, even when allogeneic cells have H-2 or background 
genes homologous with AKR.  Leukemic cells do,  however,  suppress cells that 
are unable to respond allogeneically to leukemic AKR cells, such as cells of the 
Fts of AKR.  Suppression of normal AKR antibody responses by leukemic AKR 
cells may be overcome by addition  of irradiated  allogeneic cells.  The fact that 
leukemic AKR cells are able to suppress normal lymphocyte responses may be of 
significance in pathogenesis of leukemia in these mice. 
Note Added in Proof.  The leukemic and normal AKR mice used in these experiments 
were female. We now have evidence that suppression across sex barriers is infrequent, 
probably due to recognition of male-female antigenic differences. 
We  thank  Garry J.  McMinds  and  Anna  Trendevilov for technical  help  and  Doctors 
Edward Boyse and Frank Lilly for the AKR.H-2  b and C57BL/6.AKR mice. 
Received for publication 12 November 1975. 
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